Holen Sie sich die Stockscreener-App
9.18
4.47%
-0.43
Schlusskurs vom Vortag:
$9.61
Offen:
$9.86
24-Stunden-Volumen:
567.44K
Relative Volume:
0.53
Marktkapitalisierung:
$531.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-4.883
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
+0.00%
1M Leistung:
+0.33%
6M Leistung:
+116.25%
1J Leistung:
+116.51%
1-Tages-Spanne:
$9.18
$10.03
1-Wochen-Bereich:
$9.06
$10.03
52-Wochen-Spanne:
$2.612
$13.60
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Vergleichen Sie OMER mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
9.18 | 531.98M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
Omeros Corporation Announces Statistical Analysis Results for Expanded Access ProgramSeattle, Washington–(BUSINESS WIRE)–Feb 20, 2025–Omeros Corporation (NASDAQ: OMER) announced today the statistical analysis results related to the expande - Defense World
Omeros announces results for narsoplimab expanded access program - Yahoo Finance
Can This Drug Cut Death Risk by 66% in Transplant Patients? New Data Reveals Breakthrough - StockTitan
Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50 - MarketBeat
Breakthrough TA-TMA Treatment Data: Narsoplimab Shows Promising Results in 128-Patient Study - StockTitan
Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program - BioSpace
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes Of Narsoplimab Treatment For Ta-Tma - Marketscreener.com
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company - Yahoo Finance
SG Americas Securities LLC Has $241,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Navigating OMER Stock: Omeros Corporation Journey - The InvestChronicle
Stordahl Capital Management Inc. Purchases New Shares in Omeros Co. (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Trading Up 5.3%Here's What Happened - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Down 4.4%Here's Why - MarketBeat
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Cantor Fitzgerald Forecasts Omeros FY2025 Earnings - Defense World
Omeros (NASDAQ:OMER) Shares Gap DownTime to Sell? - MarketBeat
Cantor Fitzgerald Comments on Omeros FY2025 Earnings - MarketBeat
Omeros’ (OMER) Hold Rating Reiterated at Needham & Company LLC - Defense World
Barclays PLC Acquires 51,873 Shares of Omeros Co. (NASDAQ:OMER) - MarketBeat
Barclays PLC Has $376,000 Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Earns “Buy” Rating from D. Boral Capital - Defense World
Omeros Corporation Announces Statistical Sensitivity Analyses Results for Narsoplimab - Defense World
Needham & Company LLC Reaffirms Hold Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Up 5.5%Time to Buy? - MarketBeat
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - MarketBeat
Narsoplimab shows promise in reducing mortality for TA-TMA patients - MSN
Omeros Co. (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Personal Finance - Business Wire
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint - Business Wire
Jane Street Group LLC Has $231,000 Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
When the Price of (OMER) Talks, People Listen - Stock Traders Daily
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
United Rentals (URI-N) QuotePress Release - The Globe and Mail
Omeros (NASDAQ:OMER) Stock Price Down 3.1%Time to Sell? - MarketBeat
Geode Capital Management LLC Has $5.32 Million Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Acquired by Barclays PLC - Defense World
Omeros (NASDAQ:OMER) Trading Up 10.3%Time to Buy? - MarketBeat
Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat
State Street Corp Has $4.87 Million Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Shares Up 3.6% – Here’s Why - Defense World
MML Investors Services LLC Purchases 3,000 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Stock Price Up 3.6%What's Next? - MarketBeat
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):